This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Pyruvate kinase deficiency anemia(pyruvate kinase deficiency anemia)(Pyruvate kinase deficiency anaemia) — mechanism- and pharmacology-focused description

ICD-10: D55.2 | V code: V164 | Synonyms: PK deficiency anemia, PK deficiency, PKLR deficiency, Pyruvate kinase deficiency hemolytic anemia, Erythrocyte PK deficiency

Contents

  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Historical context of the discovery of PK deficiency

The history of pyruvate kinase (PK) deficiency began in 1961, when Valentine, Oski, Diamond, and colleagues first reported a marked reduction of erythrocyte PK activity in patients with hereditary nonspherocytic hemolytic anemia (HNSHA). This discovery brought a shift in the recognition that disorders of erythrocyte metabolism can cause chronic hemolytic anemia, and later became the foundation for the classification system of various erythrocyte enzymopathies. In the 1960s–70s, marked accumulation of 2,3-DPG was observed in patients with PK deficiency, and it was found that this actually acts as a compensatory mechanism that improves tissue oxygen delivery. This discovery was an important contribution that deepened the understanding of oxygen transport physiology.

PKLR gene cloning and the molecular era

In 1991–1992, the PKLR gene was identified and cloned on chromosome 1q22, and understanding at the molecular level began in earnest. Over the following 30 or so years, more than 260 pathogenic variants have been reported, and structural biology and enzyme kinetics studies on the functional impact of variants have been actively conducted. In the 2010s, the crystal structure of the PK protein was analyzed and the allosteric regulatory mechanism was elucidated at the atomic level, laying the theoretical foundation for the later development of small-molecule PK activator therapeutics.

The development of mitapivat and clinical innovation

In the late 2010s, Agios Pharmaceuticals developed a small-molecule PK activator that increases erythrocyte ATP in patients with PK deficiency. In 2019, results of the phase 3 ACTIVATE trial were published, confirming a significant hemoglobin increase in non-transfusion-dependent adult patients with PK deficiency, and in 2022 the FDA approved mitapivat (Pyrukynd). This was the first approval of a small-molecule disease-modifying therapy in the field of erythrocyte enzymopathies, changing the treatment paradigm for PK deficiency, which had long relied solely on transfusion and splenectomy.

2. Causes

Position of PK in glycolysis and reaction mechanism

Pyruvate kinase (PK) is the enzyme that catalyzes the 10th and final reaction of glycolysis. The specific reaction is as follows: phosphoenolpyruvate (PEP) + ADP → pyruvate + ATP. This reaction is the second step of substrate-level phosphorylation, and 2 of the 4 ATP molecules produced in the whole of glycolysis are produced at this step. In mature erythrocytes, the PK reaction is significant as the last means of producing ATP without mitochondria.

The PK isozyme system and the PKLR gene

Humans have two PK genes. The PKLR gene encodes PK-R and PK-L, expressed in erythrocytes (R type, erythrocyte) and liver (L type, liver), respectively, and the PKM gene produces PK-M1 and PK-M2, expressed in muscle and brain. HNSHA due to PK deficiency occurs when the PK-R isozyme is impaired by variants in the PKLR gene; PKM gene variants do not cause HNSHA. PK-R normally forms a homotetramer to be active, and its activity is increased by the allosteric activator fructose-1,6-bisphosphate (FBP).

Functional classification of PKLR variants

Pathogenic variants of the PKLR gene can be classified into three groups according to their functional impact. First, variants that decrease the maximal velocity (Vmax) of the enzyme (enzyme destabilization, increased protein degradation); second, variants that increase the affinity constant (Km) for the substrate PEP (impaired enzyme-substrate binding); and third, variants that damage the FBP allosteric activation site (loss of allosteric response). Clinical severity is closely related to the degree of residual PK activity, and enzyme function in a low-PEP-concentration environment (the slow blood flow compartment of the spleen) is particularly important in determining clinical outcome.

3. Genetics

PKLR gene structure and tissue-specific expression

The PKLR gene is located on the long arm of chromosome 1 (1q22) and consists of 12 exons. PK-R (erythrocyte type) uses exon 1 (R-specific) + exons 2–12, and PK-L (liver type) uses exon 1' (L-specific) + exons 2–12. The two isozymes differ only in the N-terminal portion and are otherwise identical. Expression of the PKLR gene in erythrocytes is regulated by erythroid-specific transcription factors (GATA-1, KLF1, etc.).

Autosomal recessive inheritance and genotype-phenotype correlation

PK deficiency due to PKLR gene variants is inherited in an autosomal recessive manner. Most patients are compound heterozygotes carrying two different variants. The genotype-phenotype correlation has been only partially established, and clinical severity varies even among patients carrying the same variants. This is because not only the type of variant but also multiple variables such as the individual's glycolytic capacity, splenic function, and hematopoietic capacity affect the clinical phenotype.

Founder effect and population genetics

Certain PKLR variants are observed at high frequency in specific ethnic groups due to the founder effect. In Northern European Caucasians, the c.1529G>A (p.Arg510Gln) variant is the most common, and in the Spanish Gypsy (Roma) population, the c.1456C>T (p.Arg486Trp) variant shows a high frequency. In populations carrying these founder variants, the heterozygous carrier frequency is estimated to reach 1/50–1/100. The distribution of PKLR variants in East Asia has not yet been sufficiently studied, and systematic research on Korea-specific variants is needed.

4. General epidemiology

Estimated worldwide prevalence

The worldwide prevalence of PK deficiency has been estimated in the most recent data (Bianchi et al., 2019) at an incidence of about 51 per 20,000 births (51/1,000,000 births). This is about 25 times higher than earlier estimates (1 per 510,000 births), reflecting the possibility that diagnoses of mild patients were missed in past studies. The heterozygous carrier frequency in Caucasian populations is estimated at about 1/122.

Status of PK deficiency in Korea

In Korea, around several dozen cases of PK deficiency are registered in the national rare disease registry database. Domestically, the diagnosis rate is improving with the spread of NGS-based diagnostic panels, and some specialized hematology centers in Korea provide PKLR variant analysis and PK enzyme activity measurement. There are as yet no large-scale epidemiological studies on the frequency of Korean-specific variants.

Age, sex, and clinical spectrum

PK deficiency occurs with equal frequency in males and females, and clinical severity is extremely broad, ranging from hydrops fetalis to asymptomatic in adulthood. In the worldwide PK deficiency natural history study (PKD Natural History Study, Grace et al., 2018), about 66% of all enrolled patients were transfusion-dependent and 52% had undergone splenectomy, and even in non-transfusion-dependent patients the median Hb was about 9.7 g/dL, confirming a state of chronic anemia.

5. Pathophysiology

Position of PK in the overall flow of energy metabolism in mature erythrocytes

Energy metabolism in mature erythrocytes consists of glycolysis and the pentose phosphate pathway (PPP). About 90% of glucose consumption occurs through glycolysis, and 10% produces NADPH through the PPP. In glycolysis, ATP is produced at two steps: the phosphoglycerate kinase (PGK) reaction and the pyruvate kinase (PK) reaction. Each produces 2 molecules of ATP per molecule of glucose, so the net production of glycolysis is 2 molecules of ATP. Because PK is the final step that produces the latter 2 of these ATP molecules, PK deficiency has the effect of blocking half of the erythrocyte ATP supply. In PK-deficient erythrocytes, upstream intermediates such as PEP, 2-phosphoglycerate, and 3-phosphoglycerate accumulate, and production of pyruvate and lactate decreases.

Consequences of ATP depletion in mature erythrocytes lacking mitochondria

In mature erythrocytes that have lost their nucleus and mitochondria, ATP depletion causes complex cellular damage. First, reduced Na+/K+-ATPase function raises intracellular Na+ concentration and lowers K+ concentration, causing osmotic swelling. Next, reduced function of the ATP-dependent membrane phospholipid flippase (P4-ATPase/flippase) exposes phosphatidylserine (PS) on the outer membrane surface, and splenic macrophages that recognize it prematurely phagocytose the erythrocytes. Third, lack of the ATP needed to maintain the phosphorylation state of cytoskeletal proteins (spectrin, ankyrin, etc.) and membrane-cytoskeleton interactions reduces membrane deformability, so the cells cannot pass through the narrow passages between endothelial cells of the spleen (endothelial slits) and are destroyed. The spleen, in particular, is a site where ATP production in PK-deficient erythrocytes is further suppressed because of slow blood flow and a low-glucose, low-oxygen environment, making the spleen the main site of destruction of PK-deficient erythrocytes.

2,3-DPG accumulation and right shift of the oxygen dissociation curve: physiological compensation

One of the most characteristic biochemical changes in PK-deficient erythrocytes is the marked accumulation of 2,3-bisphosphoglycerate (2,3-DPG). 2,3-DPG is the product of a side pathway (Luebering-Rapoport pathway) in which it is formed from the glycolytic intermediate 1,3-BPG (1,3-bisphosphoglycerate) by DPG mutase. In PK deficiency, as all glycolytic intermediates upstream of PEP accumulate, 1,3-BPG also increases, and as a result 2,3-DPG rises to several times normal. High 2,3-DPG concentrations bind to the beta-globin central cavity of the hemoglobin tetramer and stabilize hemoglobin in the deoxygenated (T) conformation with low oxygen affinity. As a result, the oxyhemoglobin dissociation curve shifts to the right, and the P50 value (the oxygen partial pressure at which 50% of blood hemoglobin is bound to oxygen) increases. In practice, this means more oxygen can be delivered to tissues at the same oxygen partial pressure, partially explaining why clinical symptoms are relatively mild compared with the hemoglobin level in patients with PK deficiency. After splenectomy, the life span of PK-deficient erythrocytes is prolonged (reticulocytes with higher 2,3-DPG predominate instead of aged erythrocytes with low 2,3-DPG capacity), but a paradoxical effect may also occur in which tissue oxygen delivery capacity becomes relatively lower even though the hemoglobin level improves.

6. Symptoms

Clinical spectrum: from hydrops fetalis to mild anemia in adulthood

The clinical manifestations of PK deficiency show an extremely diverse spectrum depending on the combination of variants carried. The most severe phenotype is intrauterine hydrops fetalis, presenting with high-output heart failure, ascites, and generalized edema due to severe fetal anemia, and survival is difficult without intrauterine transfusion. After birth, severe neonatal jaundice requires exchange transfusion, and if untreated, neurological damage due to kernicterus occurs. In mild phenotypes, patients may remain asymptomatic until adulthood, with anemia first discovered during stresses such as pregnancy, infection, or surgery.

Symptoms after adulthood and pregnancy-related manifestations in heterozygous carriers

Heterozygous carriers are generally clinically healthy, but during pregnancy, physiological hemodilution and increased fetal erythropoiesis may push the maternal compensatory capacity to its limit, and mild worsening of hemolysis may occur. In addition, with parvovirus B19 infection, aplastic crisis in patients with chronic hemolytic anemia causes temporary complete arrest of erythropoiesis, resulting in life-threatening acute worsening of anemia.

7. Signs

Physical examination findings

Physical signs observed in patients with PK deficiency are the typical pattern of chronic hemolytic anemia, with conjunctival pallor, scleral icterus, and skin jaundice being the most common. Splenomegaly is common because erythrocyte destruction due to hemolysis occurs mainly in the spleen, and massive spleens ranging from several centimeters to, in severe cases, extending down to the pelvic region are also observed. In children, skull deformity, frontal bossing, and prominent cheekbones due to chronic anemia may occur. In adult patients who have undergone splenectomy, post-splenectomy findings such as echinocytes, traces of Heinz bodies, and target cells are observed on peripheral blood smear.

Laboratory findings

Complete blood count shows characteristic normocytic or macrocytic anemia and marked reticulocytosis (10–50%). Laboratory indicators of hemolysis include elevated serum indirect bilirubin, elevated LDH, and decreased haptoglobin. A marked increase in intraerythrocytic 2,3-DPG concentration to several times normal (normal: 4–5 mmol/L, PK deficiency: 10–20 mmol/L) is a finding specific to PK deficiency, and measuring it aids diagnosis. The DAT (direct antiglobulin test) is negative, and hemoglobin electrophoresis is normal.

8. Screening

Initial screening algorithm

A specific screening program for PK deficiency is currently not standardized. In patients with clinically unexplained chronic hemolytic anemia, hemolytic anemia is confirmed using a basic screening panel (complete blood count, reticulocytes, peripheral blood smear, DAT, serum bilirubin·LDH·haptoglobin), then hereditary spherocytosis, G6PD deficiency, and autoimmune hemolytic anemia are excluded, after which PK deficiency is suspected. In neonates in whom PK deficiency is strongly suspected or from families with already confirmed cases, PK enzyme activity measurement and molecular analysis are performed early.

Selective use of 2,3-DPG measurement

Measurement of intraerythrocytic 2,3-DPG concentration can be used as a specific adjunctive screening test for PK deficiency. When 2,3-DPG is markedly increased (2 or more times normal), PK deficiency is likely; conversely, when 2,3-DPG is low or normal, deficiency of upper glycolytic enzymes (HK, etc.) should be considered rather than PK deficiency. 2,3-DPG measurement is a relatively simple test that aids biochemical differentiation of PK deficiency from other HNSHA, including HK deficiency.

9. Diagnosis

Quantitative measurement of PK enzyme activity

PK deficiency is confirmed by quantitative measurement of erythrocyte PK enzyme activity (spectrophotometric enzyme assay). The test uses phosphoenolpyruvate (PEP) and ADP as substrates and lactate dehydrogenase (LDH) as the coupling enzyme, measuring the rate of NADH consumption at 340 nm. By measuring under two conditions, low PEP concentration (0.3 mM) and high PEP concentration (3.0 mM), abnormal allosteric response can be additionally assessed. Results are expressed in IU/g Hb. The higher the reticulocyte count, the more the deficiency is underestimated due to the high PK activity of young erythrocytes, so correction for reticulocyte count or retesting after separation of aged erythrocytes is needed.

Molecular analysis of the PKLR gene

After reduced PK enzyme activity is confirmed, PKLR gene variant analysis is performed. Currently, Sanger sequencing, NGS panels (erythrocyte enzymopathy panel, rare hematological disorder panel), and whole exome sequencing (WES) are used. Detected variants are classified for pathogenicity with reference to PKLR variant databases (PKLRbase, ClinVar, etc.) and functional study results. In compound heterozygous patients, phasing analysis to confirm that the two variants are located on different alleles is essential for genetic counseling.

Additional biochemical testing: analysis of erythrocyte metabolites

Erythrocyte metabolite (metabolomics) analysis can directly confirm the biochemical features of PK deficiency (PEP accumulation, increased 2,3-DPG, decreased pyruvate) and is useful for differentiation from HK deficiency (decrease in intermediates throughout glycolysis) or other HNSHA. Mass spectrometry-based erythrocyte metabolite panels are provided by specialized research institutions and are used particularly for functional interpretation of rare variants.

10. Treatment

Mechanism of action of mitapivat: allosteric PK activation

Mitapivat (AG-348, brand name Pyrukynd) is an allosteric activator of the PK-R enzyme. It binds directly to the R544C binding site (AG-348 binding pocket) near the FBP (fructose-1,6-bisphosphate) binding site of the PK-R tetramer, stabilizing the PK-R enzyme in the active (R state) tetrameric conformation. The principle is pharmacological mimicry of the allosteric activation mechanism of wild-type (normal) PK-R. PK-R activation by mitapivat amplifies residual enzyme activity in variant PK-R whose substrate affinity has been reduced or whose allosteric response has been impaired by pathogenic variants, allowing ATP to be produced more efficiently from PEP in erythrocytes. As a result, intraerythrocytic ATP concentration increases, 2,3-DPG concentration decreases, and erythrocyte life span is prolonged, reducing hemolysis.

Clinical study results and indications

In the 2019 phase 3 ACTIVATE trial, mitapivat administration in non-transfusion-dependent adult patients with PK deficiency produced a response of Hb increase of 1.5 g/dL or more (primary endpoint achieved) in 40%, versus 0% response in the placebo group, demonstrating a statistically significant difference. In the 2021 phase 3 ACTIVATE-T trial, the mitapivat group also significantly reduced transfusion frequency compared with placebo in transfusion-dependent patients with PK deficiency. The FDA in 2022 and the EMA in 2023 each approved mitapivat for adult patients with PK deficiency. Clinical trials in pediatric patients are ongoing.

Other treatments: transfusion, splenectomy, hematopoietic stem cell transplantation

In patients for whom mitapivat is not applicable or whose response is insufficient, conventional treatments are maintained. Red blood cell transfusion is performed for severe anemia (Hb < 7 g/dL) or marked clinical symptoms, and in transfusion-dependent patients, iron chelation therapy (deferasirox, deferoxamine, deferiprone) is given concurrently to manage iron overload. Splenectomy contributes to increased Hb and reduced transfusion frequency but entails an increased risk of OPSI and a risk of portal vein thrombosis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered as curative treatment in severe pediatric patients.

11. Prognosis

Changes in prognosis before and after mitapivat

Before the approval of mitapivat, the prognosis of patients with PK deficiency was determined mainly by transfusion dependence and the resulting complications of iron overload. In transfusion-dependent patients, iron overload led to organ damage such as liver cirrhosis, diabetes, hypogonadism, and heart failure. With the advent of mitapivat, reduced transfusion frequency or achievement of transfusion independence became possible in some patients, and a pharmacological benefit of improved erythrocyte oxygen-carrying efficiency due to decreased 2,3-DPG was also confirmed. However, mitapivat does not show equal efficacy for all variants, and its effect is limited particularly in nonsense variants or large deletion variants in which protein synthesis itself is blocked.

Long-term complications and quality of life

Even in appropriately treated patients, complications such as pigment gallstones (occurring in at least more than 50% of adult patients with PK deficiency), cholecystitis, post-splenectomy thrombosis, and osteoporosis reduce quality of life. In the worldwide PK deficiency natural history study, quality-of-life scores of adult patients with PK deficiency were markedly lower than those of the general population, and fatigue and limitation of physical activity in particular were identified as major determinants of quality of life.

12. Prevention

Genetic counseling and prenatal and perinatal management

The most important element in the prevention of PK deficiency is genetic counseling and family testing in families of confirmed patients. When both parents are confirmed as PKLR carriers, fetal involvement is determined during pregnancy through prenatal molecular diagnosis (chorionic villus sampling or amniocentesis), and for affected fetuses, an early intervention plan (intensive monitoring of neonatal jaundice, preparation for exchange transfusion, planning of a transfusion schedule) is established in advance. In families who have already had an infant with PK deficiency, prenatal diagnosis is strongly recommended in subsequent pregnancies.

Active prevention of iron overload and complications

In transfusion-dependent patients with PK deficiency, early detection and timely treatment of iron overload is a key strategy for preventing organ damage. When serum ferritin exceeds 1000 ng/mL or rises persistently, initiation of iron chelation therapy is considered, and hepatic iron concentration is periodically assessed by liver MRI (T2*). Gallbladder ultrasound is performed regularly to prevent pigment gallstones, and if gallstones are found, early cholecystectomy is considered. In patients who have undergone splenectomy, keeping pneumococcal, meningococcal, and Haemophilus influenzae type b vaccinations up to date and promptly visiting a medical facility and receiving antibiotic treatment when febrile are essential elements of OPSI prevention.

13. References

  1. Valentine WN, Tanaka KR, Miwa S. A specific erythrocyte glycolytic enzyme defect (pyruvate kinase) in three subjects with congenital nonspherocytic hemolytic anemia. Trans Assoc Am Physicians. 1961;74:100-110.
  2. Grace RF, Rose C, Lainez-Mas B, et al. Mitapivat in pyruvate kinase deficiency (ACTIVATE trial). N Engl J Med. 2019;381(10):933-944.
  3. Rab MAE, van Oirschot BA, Kostek M, et al. ACTIVATE-T: mitapivat in transfusion-dependent PK deficiency. Blood. 2021;138(26):2801-2811.
  4. Grace RF, Laakso M, Dardenne MN, et al. Clinical spectrum of pyruvate kinase deficiency: data from the PKD Natural History Study. Blood. 2018;131(20):2183-2192.
  5. Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. Pyruvate kinase deficiency: the genotype-phenotype association. Blood Rev. 2007;21(4):217-231.
  6. Bianchi P, Fermo E, Glader B, et al. Addressing the diagnostic gaps in pyruvate kinase deficiency. Am J Hematol. 2019;94(1):149-161.
  7. Kung C, Hixon J, Bowers S, et al. Small molecule activation of PKM2 in cancer cells induces serine catabolism. Sci Rep. 2012;2:926.
  8. Kung C, Hixon J, Choe S, et al. AG-348 is a first-in-class allosteric activator of erythrocyte pyruvate kinase. Blood. 2017;130(1):25-36.
  9. van Beers EJ, van Straaten S, Morton DH, et al. Prevalence and management of iron overload in pyruvate kinase deficiency. Haematologica. 2019;104(2):e51-e53.
  10. Laurance M, Lauer FT, Byers H, et al. 2,3-DPG changes resulting from mitapivat treatment. Am J Hematol. 2021;96(8):987-993.
  11. Prchal JT. Red cell enzymopathies. In: Kaushansky K, et al., eds. Williams Hematology. 10th ed. McGraw-Hill; 2021:Chapter 47.